Saturday, June 6, 2026

#Bundibugyo virus disease #outbreak in #DRC: current #trajectory and potential #risk for a Pandemic Emergency

 


{Excerpt}

On May 15, 2026, DR Congo declared the 17th orthoebolavirus disease outbreak—the third in the country in two decades caused by the Bundibugyo virus variant (Orthoebolavirus bundibugyoense)—in the conflict affected north-eastern province of Ituri.1 The next day, the WHO Director-General determined this event a Public Health Emergency of International Concern (PHEIC) and on May 18, the Africa Centres for Disease Control and Prevention (CDC) declared a Public Health Emergency of Continental Security.2 10 days earlier, WHO received an alert about a cluster of unexplained deaths, including deaths among health workers, in the Mongbwalu Health Zone. Initial laboratory results were negative for orthoebolavirus and reagents from Ituri were reasonably provisioned for Ebola virus.1

(...)

Source: 


____

#Human ACE2‑specific benzothiazole-based allosteric #inhibitor against pan ‑ #sarbecoviruses

 


Abstract

Emerging SARS‑CoV‑2 variants and related zoonotic sarbecoviruses rely on ACE2 for cell entry, motivating host‑directed antivirals that block spike-ACE2 interaction. Here, we characterize MB‑32, a benzothiazole small molecule that binds ACE2, selectively disrupts binding of SARS‑CoV‑2 spike receptor‑binding domain to ACE2, and preserves ACE2 enzymatic activity across species. MB‑32 potently inhibits entry of SARS‑CoV‑2 variants, SARS‑CoV‑1 and diverse bat/pangolin sarbecoviruses in ACE2‑expressing cells, while sparing vesicular stomatitis virus and authentic MERS‑CoV, indicating non‑virucidal, ACE2‑focused activity. Biochemical and biophysical analyses, supported by ACE2 mutagenesis, support a model in which MB‑32 engages a non‑catalytic surface pocket on the ACE2 N‑terminal helix to allosterically disrupt spike attachment. Intranasal MB‑32 achieves high airway concentrations, protects male ACE2‑transgenic mice and hamsters from SARS‑CoV‑2 disease, and prevents contact transmission of Omicron‑lineage viruses without detectable cardiovascular toxicity. These findings establish MB‑32 as a host‑targeted ACE2 entry inhibitor and provide a framework for small‑molecule ACE2‑directed antivirals against current and future sarbecovirus spillovers.

Source: 


Link: https://www.nature.com/articles/s41467-026-73944-x

____

Cross-reactive #Bundibugyo #antibody responses after licensed #Ebola #vaccines

 


Abstract

Background 

The ongoing Bundibugyo virus disease (BDBV) outbreak in Central Africa highlights the absence of approved vaccines specifically targeting BDBV. Whether licensed Zaire ebolavirus (EBOV) vaccines induce cross-reactive immunity against BDBV remains largely unknown.

Methods 

We performed an immunogenicity analysis using serum samples from participants enrolled in the PREVAC randomized clinical trial evaluating licensed Ebola vaccine strategies in West Africa. Samples collected at day 28 (D28) and month 3 (M3) following vaccination with rVSVΔG-ZEBOV-GP or Ad26.ZEBOV/MVA-BN-Filo were assessed using a multiplex Luminex assay against glycoproteins from multiple filoviruses, including EBOV Kikwit, EBOV Mayinga, BDBV, Sudan virus, Reston virus, and Marburg virus.

Results 

A total of 179 samples were analysed. Detectable cross-reactive antibody responses against BDBV were observed across vaccine groups, timepoints, and age categories. However, BDBV responses remained substantially lower than homologous EBOV responses. In rVSV recipients, median BDBV responses (net MFI) reached 282 (IQR 164–644) at D28 compared with 1788 (832–3311) against the homologous Kikwit antigen. Similar patterns were observed following rVSV booster vaccination and Ad26.ZEBOV/MVA-BN-Filo vaccination. The heterologous Ad26/MVA regimen demonstrated increasing BDBV responses between D28 and M3.

Conclusions 

Licensed EBOV vaccines induced detectable but quantitatively reduced cross-reactive antibody responses against BDBV. Although no direct assessment of vaccine efficacy against BDBV disease was possible, these findings support the plausibility of partial heterologous immunity following EBOV vaccination. In the absence of approved BDBV-specific vaccines, these data support the urgent evaluation of currently available Ebola vaccines during BDBV outbreaks and reinforce the importance of developing broadly protective pan-filovirus vaccines.


Competing Interest Statement

The authors have declared no competing interest.


Clinical Trial

NCT02876328

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.05.27.26354223v1

____

The #canine respiratory #epithelium is a permissive #ecosystem for #influenza interspecies #transmission and emergence

 


Abstract

The outcome of virus spillover ranges from dead-end infections to pandemics and is underpinned by host-pathogen interactions as well as evolutionary and epidemiological processes. The emergence of novel influenza A viruses (IAVs) has been associated with reassortment events involving multiple species, highlighting the importance of reservoir and intermediate hosts in viral emergence. Highly pathogenic H5N1 IAVs of the 2.3.4.4b genotype have caused a panzootic affecting a broad range of mammals. The role of dogs -arguably the most popular companion animal and a natural host of IAVs- in the ecology of IAVs under this new zooepidemiological scenario is unknown. To address this, we characterised the glycome of the dog respiratory epithelium, infected canine tracheal explants with multiple IAVs (including canine H3N2 and H3N8, equine H3N8, avian H3N8 and H5N1, swine H1N1, human H1N1 and H3N2, and bovine H5N1 viruses), and determined their cellular tropism. We show that the respiratory tract of dogs presents abundant sialylated glycans known to act as IAV receptors. Further, most IAVs (including 2.3.4.4b viruses) infected and replicated in dog tracheas, targeting mainly ciliated cells. Serological testing showed evidence of influenza spillover infections in dogs from the UK. Overall, our results show that the canine respiratory tract can provide a suitable environment for the generation of new IAVs. Given the multi-host contact networks of dogs in nature, they could act as recipients, bridging hosts, and/or mixing vessels for multiple IAV lineages, playing a central role in the ecology of influenza emergence.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Medical Research Council, https://ror.org/03x94j517, MR/Y03368X/1, MC_UU_0034/2, MC_UU_0034/3

Biotechnology and Biological Sciences Research Council, BB/Y007093/1, BB/Y007298/1, BBS/E/PI/230001A, BBS/E/PI/230002A, BBS/E/PI/230002B, BBS/E/PI/230001C

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.06.04.730051v1

____

History of Mass Transportation: The Diesel Shunter Class 89 of the Romanian Railways in Pitesti

 


{Click on Image to Enlarge}


By Dr2005 - Wk Ro, http://ro.wikipedia.org/wiki/Imagine:89-0585-3-Pitesti-002.jpg, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=3553605

Source: 


Link: https://en.wikipedia.org/wiki/Rolling_stock_of_the_Romanian_Railways

____

#Coronavirus Disease Research #References (AMEDEO, June 6 '26)

 


    Ann Intern Med

  1. KOUTOURATSAS T, Dammad T, Mylonakis E
    In outpatients with COVID-19 during Omicron variant circulation, some antivirals reduce time to recovery.
    Ann Intern Med. 2026 Jun 2. doi: 10.7326/ANNALS-26-01878.
    PubMed         Abstract available


    Clin Infect Dis

  2. BONTEN M, Essink B, Hanning N, Leroux-Roels I, et al
    Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged >/=50 years: a phase 3, randomized, non-inferiority trial.
    Clin Infect Dis. 2026 Jun 4:ciag344. doi: 10.1093.
    PubMed         Abstract available

  3. BRAMANTE CT, Stewart TG, Boulware DR, McCarthy MW, et al
    Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.
    Clin Infect Dis. 2026 Jun 4:ciag335. doi: 10.1093.
    PubMed         Abstract available

  4. LIU C, Okoli GN, Chen R, Sullivan SG, et al
    SARS-CoV-2 vaccination and attenuation of breakthrough infection severity: A systematic global review and meta-analysis.
    Clin Infect Dis. 2026 Jun 1:ciag346. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  5. JURICA JM, Smith DM, Abeles S, Torriani FJ, et al
    Discontinuing contact precautions for COVID-19: the science says its time.
    Infect Control Hosp Epidemiol. 2026 Jun 5:1-3. doi: 10.1017/ice.2026.10482.
    PubMed         Abstract available

  6. ALSOUBANI M, Andujar G, Campion M
    Socioeconomic and racial review of COVID-19 antiviral prescriptions: a large health system cohort.
    Infect Control Hosp Epidemiol. 2026 Jun 1:1-6. doi: 10.1017/ice.2026.10473.
    PubMed         Abstract available


    Int J Infect Dis

  7. VEIJER C, van Asselt ADI, van Zon SKR, Rosmalen JGM, et al
    Healthcare Resource Use and Costs under Pandemic Circumstances in The Netherlands: Results from the Lifelines COVID-19 Cohort.
    Int J Infect Dis. 2026 Jun 3:108854. doi: 10.1016/j.ijid.2026.108854.
    PubMed         Abstract available

  8. ABU-RADDAD LJ, Ayoub HH, Coyle P, Tang P, et al
    Routine SARS-CoV-2 Testing Frequency and Risk of Severe COVID-19: A Nationwide Population-Based Study.
    Int J Infect Dis. 2026 Jun 2:108851. doi: 10.1016/j.ijid.2026.108851.
    PubMed         Abstract available

  9. LAW AHT, Wong JY, Lin Y, Cowling BJ, et al
    Sex differences in COVID-19 infection and mortality in Hong Kong.
    Int J Infect Dis. 2026 Jun 2:108852. doi: 10.1016/j.ijid.2026.108852.
    PubMed         Abstract available

  10. LIN Y, Wu P, Lau EHY, Blais J, et al
    SARS-CoV-2 viral shedding and vaccination?modified effects of oral antivirals in older COVID-19 patients: a retrospective cohort study in Hong Kong.
    Int J Infect Dis. 2026 Jun 1:108848. doi: 10.1016/j.ijid.2026.108848.
    PubMed         Abstract available


    J Med Virol

  11. CHEN Y, Lan Y, Zhao A, Zhang Y, et al
    Anti-Zika Virus Activity of Azvudine via Inhibition of RNA Replication by Its Active Triphosphate Form.
    J Med Virol. 2026;98:e71000.
    PubMed         Abstract available


    J Thorac Oncol

  12. XU X, Saad MB, Grippin A, Xu H, et al
    Brief Report: SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated with Radiotherapy.
    J Thorac Oncol. 2026 Jun 1:103956. doi: 10.1016/j.jtho.2026.103956.
    PubMed         Abstract available


    J Virol

  13. FAN L, Gao X, Feng W, Huang Q, et al
    SARS-CoV-2 ORF3a suppresses host antiviral interferon responses by promoting STUB1-mediated PTEN proteasomal degradation.
    J Virol. 2026 Jun 2:e0018626. doi: 10.1128/jvi.00186.
    PubMed         Abstract available


    Lancet

  14. KARIM SA, Mahomed S, Lewis L, Karim SSA, et al
    Urgent need for a reliable rapid diagnostic test for the Ebola epidemic caused by Bundibugyo virus in Africa.
    Lancet. 2026 Jun 2:S0140-6736(26)01093-7. doi: 10.1016/S0140-6736(26)01093.
    PubMed        


    Lancet Infect Dis


  15. Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet Infect Dis. 2026 Jun 2:S1473-3099(26)00194.
    PubMed         Abstract available


    Science

  16. EMANUEL N, Harrington E, Pallais A
    Home alone: Remote work, isolation, and mental health.
    Science. 2026;392:eaec7671.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 6 '26)

 


    Arch Virol

  1. PERDANA WY, Tsuneki-Tokunaga A, Rahmi KA, Hinay AA Jr, et al
    In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability.
    Arch Virol. 2026;171:200.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  2. SHAO S, Dong ZY, Kang ZY, Zhang H, et al
    Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines.
    Biochem Biophys Res Commun. 2026;825:153958.
    PubMed         Abstract available


    Epidemiol Infect

  3. SANE J
    Rebuilding trust in public health: Beyond polarization.
    Epidemiol Infect. 2026;154:e71.
    PubMed         Abstract available

  4. HASSELL K, Andrews N, Dabrera G, Kall M, et al
    Acute COVID-19 mortality in England in the omicron era: a national-level matched cohort study.
    Epidemiol Infect. 2026;154:e70.
    PubMed         Abstract available


    J Infect Dis

  5. PRASERT K, Praphasiri P, Ditsungnoen D, Naosri S, et al
    Risk of hospitalization related to influenza A(H3N2) virus subclade K, Thailand, June-December 2025.
    J Infect Dis. 2026 May 31:jiag283. doi: 10.1093.
    PubMed         Abstract available


    J Neurosurg Pediatr

  6. ANDERSON MG, Pindrik J, Michelow IC, Anuar A, et al
    Pediatric sinogenic and otogenic intracranial infections requiring neurosurgical intervention: a North American multicenter study in the era of COVID-19.
    J Neurosurg Pediatr. 2026;37:621-631.
    PubMed         Abstract available


    J Virol


  7. CEIRR Risk Assessment Pipeline executive reports on H5N1 highly pathogenic avian influenza 2.3.4.4b, swine H1 1B.2, and H9N2 low pathogenicity avian influenza B4.7.2.
    J Virol. 2026 Jun 3:e0054526. doi: 10.1128/jvi.00545.
    PubMed         Abstract available

  8. STEARNS K, Marcink T, Pawlack E, Sobolik EB, et al
    Human parainfluenza virus 3 fusion protein cleavage: a key determinant of infection and spread.
    J Virol. 2026 Jun 3:e0212625. doi: 10.1128/jvi.02126.
    PubMed         Abstract available

  9. TURNER AH, Jaffrani SA, Kubinski HC, Ajayi DP, et al
    Rab11B is required for binding and entry of recent H3N2, but not H1N1, influenza A isolates.
    J Virol. 2026 Jun 2:e0211125. doi: 10.1128/jvi.02111.
    PubMed         Abstract available


    Pediatrics

  10. ROSTAD CA, Healy CM, Nayak JL, Parameswaran L, et al
    Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.
    Pediatrics. 2026 May 4:e2025075223. doi: 10.1542/peds.2025-075223.
    PubMed         Abstract available


    PLoS One

  11. EKWUNIFE O, Mangenah C, Ngwira L, Corbett E, et al
    Economic barriers to diagnostic equity: A multi-country analysis of patient costs for rapid SARS-CoV-2 testing in sub-Saharan Africa.
    PLoS One. 2026;21:e0350288.
    PubMed         Abstract available

  12. HEMBERG M, Hansen AL, Storgaard J, Blay-Cadanet J, et al
    MAVS is important for antiviral defense against influenza A virus in a human respiratory epithelium model.
    PLoS One. 2026;21:e0350839.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  13. RIKANI A, Di Domenico L, Sabbatini CE, Navarro V, et al
    Resetting population mobility responses under repeated nonpharmaceutical interventions: Implications for hypothesized pandemic fatigue.
    Proc Natl Acad Sci U S A. 2026;123:e2533284123.
    PubMed         Abstract available

  14. PAPADAKI M, Pavlos E, Dubourdeau M, Bailif V, et al
    Polyunsaturated fatty acid-derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19.
    Proc Natl Acad Sci U S A. 2026;123:e2534726123.
    PubMed         Abstract available

  15. GRUNDY JG, Pujols-Beltran M
    Bilingualism predicts executive function resilience after COVID-19 in aging.
    Proc Natl Acad Sci U S A. 2026;123:e2532470123.
    PubMed         Abstract available


    Vaccine

  16. DE FIGUEIREDO A, Paterson P, Lin L, Mounier-Jack S, et al
    Changing socio-demographic determinants of seasonal influenza acceptance in England during the pandemic and a framework for predicting future acceptance.
    Vaccine. 2026;85:128629.
    PubMed         Abstract available

  17. DAS S, Tenaglia BM, Riley D, Speed S, et al
    BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy.
    Vaccine. 2026;87:128774.
    PubMed         Abstract available


    Virus Res

  18. SEDAGHAT M, Najafi F, Khosravi Shademani F, Rezaeian S, et al
    Seasonal influenza vaccine and frequency of adverse events in health workers receiving two doses of AstraZeneca vaccine: a retrospective cohort study.
    Virus Res. 2026;369:199757.
    PubMed         Abstract available

Friday, June 5, 2026

Modeled #Scenario #Projections for the #Ebola Disease #Outbreak Caused by #Bundibugyo Virus, 2026 (MMWR)

 


Summary

    -- What is already known about this topic?

        ° An outbreak of Bundibugyo virus disease (BVD), a type of Ebola disease, is currently ongoing, centered in the Ituri province of the Democratic Republic of the Congo (DRC).

    -- What is added by this report?

        ° CDC used a transmission model to project outbreak growth over 3 months, by using different assumptions about the number of deaths as of May 24, 2026, and by varying the percentages of persons with BVD who are successfully identified and isolated to prevent ongoing transmission. Assuming 50 cumulative deaths as of May 24, 2026, if 70% of patients were to enter isolation, only approximately one in 20 simulations projected an outbreak exceeding 10,000 cases within 3 months.

    -- What are the implications for public health practice?

        ° Large-scale, rapid public health action is needed to control the current outbreak, already the largest known BVD outbreak, from becoming one of the largest Ebola epidemics in history.


Abstract

On May 15, 2026, the Ministries of Health in the Democratic Republic of the Congo and Uganda declared outbreaks of Bundibugyo virus disease (BVD), a type of Ebola disease. In response to reports of high numbers of suspected cases and deaths in these outbreaks, CDC simulated scenario projections to understand possible future morbidity and mortality. A branching process model with the capacity to model transmission-reducing nonpharmaceutical interventions was calibrated to three putative cumulative death counts and projected for four possible intervention scenarios ranging from poor (20%) to extremely high (95%) levels of isolation and treatment of symptomatic persons. The analysis suggested a plausible spillover event (i.e., the transmission of a virus from its natural animal reservoir to humans) in mid to late February 2026. With poor isolation levels of patients with BVD (20%) and no other interventions, the likelihood of an outbreak that exceeds 20,000 cases within 3 months is 65%. If, however a high proportion of patients were to enter isolation (70%), only a one in 20 chance is projected for an outbreak with ≥10,000 cases within 3 months. These results underscore the importance of strong public health interventions, because the current outbreak is already the largest known BVD outbreak and has the potential to quickly become one of the largest Ebola disease outbreaks ever recorded.

Source: 


Link: https://www.cdc.gov/mmwr/volumes/75/wr/mm7522e1.htm?s_cid=mm7522e1_e&ACSTrackingID=USCDC_921-DM155686&ACSTrackingLabel=Early%20Release%20%E2%80%93%20Vol.%2075%2C%20June%205%2C%202026&deliveryName=USCDC_921-DM155686

____

#Assessment of #Risk to the #US #Population from the #Ebola Disease #Outbreak Caused by #Bundibugyo Virus, 2026 (MMWR)

 


Summary

    -- What is already known about this topic?

        ° An outbreak of Bundibugyo virus disease (BVD), a type of Ebola disease, is currently occurring, centered in the Ituri province of the Democratic Republic of the Congo (DRC).

    -- What is added by this report?

        ° CDC assessed the risk posed by this ongoing outbreak to the U.S. population during the next 3 months as low.

    -- What are the implications for public health practice?

        ° Ensuring sufficient public health resources to control the outbreak in DRC will be necessary for maintaining a low risk to the U.S. population. If cases arise in the United States, there is public health capacity to contain and control an outbreak, and CDC guidance for U.S. clinicians and public health practitioners can help prevent the potential spread.


Abstract

On May 15, 2026, the ministries of health in the Democratic Republic of the Congo and Uganda declared outbreaks of Bundibugyo virus disease (BVD), a type of Ebola disease. In response to reports of high numbers of suspected cases and deaths in the affected countries, CDC assessed the risk posed by the BVD outbreak to the U.S. population during the next 3 months. This analysis used a standardized risk assessment approach that included epidemiologic data from the ongoing outbreak and historical data from previous Ebola outbreaks; the overall risk was determined by taking into account independent assessments of the likelihood of infection and the impact of infection. The assessment found that the overall risk to the U.S. population posed by the current BVD outbreak during the next 3 months is low, based on the extremely low likelihood of transmission, despite the high impact that potential infection could have and the resources that would be required to respond to the outbreak. Limitations to this assessment included uncertainties around the epidemiology of BVD as well as the current and future scope and geographic spread of the outbreak. CDC continues to monitor factors that could change this risk assessment.

Source: 


Link: https://www.cdc.gov/mmwr/volumes/75/wr/mm7522e2.htm?s_cid=mm7522e2_e&ACSTrackingID=USCDC_921-DM155686&ACSTrackingLabel=Early%20Release%20%E2%80%93%20Vol.%2075%2C%20June%205%2C%202026&deliveryName=USCDC_921-DM155686

____

Notes from the Field: #Outbreak of #Ebola Disease Caused by #Bundibugyo Virus — #DRC and #Uganda, May 2026 (MMWR, edited)

 


Summary

    ° What is already known about this topic?

        ° Bundibugyo virus has caused two previous Ebola disease outbreaks in the Democratic Republic of the Congo (DRC) and Uganda.

    ° What is added by this report?

        ° In May 2026, a large outbreak of Bundibugyo virus disease was identified in DRC and Uganda. As of June 2, a total of 378 confirmed cases and 63 confirmed deaths have been reported. No cases have been reported in the United States.

    ° What are the implications for public health practice?

        ° To help reduce the risk for continued spread of Bundibugyo virus, including potential spread beyond DRC and Uganda or importation to the United States, ongoing collaboration between CDC and international partners and coordination among U.S. government agencies are essential.


Abstract

Bundibugyo virus disease (BVD) is a type of Ebola disease, a severe and often fatal viral hemorrhagic fever (1). Bundibugyo virus was first identified in 2007, when it caused an outbreak in Uganda with 149 suspected cases and 37 deaths (2). A 2012 BVD outbreak in DRC resulted in 56 laboratory-confirmed cases and 17 deaths (3). On May 15, 2026, the ministries of health in the Democratic Republic of the Congo (DRC) and Uganda declared outbreaks of BVD. As of June 2, a total of 378 confirmed cases and 63 confirmed deaths have been reported.

Source: 


Link: https://www.cdc.gov/mmwr/volumes/75/wr/mm7522e3.htm?s_cid=mm7522e3_e&ACSTrackingID=USCDC_921-DM155686&ACSTrackingLabel=Early%20Release%20%E2%80%93%20Vol.%2075%2C%20June%205%2C%202026&deliveryName=USCDC_921-DM155686

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, June 5 '26)

 


{Excerpt}

(...)

Time Period: May 24, 2026 - May 30, 2026

    -- A(H5) Detection6 site(s) (1.4%)

    -- No Detection421 site(s) (98.6%)

    -- No samples69 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

#WHO DG's opening #remarks at launch of joint #Bundibugyo #Ebola virus continental strategic #preparedness and #response plan – 5 June 2026 (edited)

 


    Dr Jean Kaseya, Director-General of the Africa CDC,

    Dr Mohamed Yakub Janabi, WHO Regional Director for Africa,

    Dear colleagues, partners and friends from the media,

    Good morning, good afternoon and good evening, and thank you for joining us.

    Earlier this week, I returned from DRC, where I travelled to the epicentre of the Ebola outbreak in the province of Ituri.

    I saw and heard first-hand the challenges that the communities are facing, and that the government and partners are facing, as we race to control this outbreak as quickly as possible.

    The outbreak is moving fast, and we are still playing catch-up.

    But my trip to the DRC also gave me real hope that together, under the government’s leadership, we can bring this outbreak under control.

    The only way we will do that is through government leadership, community ownership and close partnership between the many actors on the ground.

    Today, WHO and Africa CDC are expressing that partnership by launching a joint continental preparedness and response plan.

    The objective is straightforward: we need to stop the outbreak where it is, support countries that are responding today, and ensure that neighbouring countries are ready to detect and act quickly if cases appear.

    There are several important features of this plan.

    First, it’s a shared plan. The only way to beat this outbreak is through close partnership, working together under the leadership of the affected countries in one coordinated effort, guided by a simple principle: one plan, one budget, one team.

    Second, this is a practical plan. It sets out what we need to do now, together, to contain the current outbreak and reduce the risk of further spread.

    Third, it’s a time-bound plan, covering June to November this year.

    And fourth, it’s a costed plan, at US$ 518 million.

    That figure represents the combined effort of WHO, Africa CDC and key partners including UNICEF, UNHCR, WFP, the IFRC and FIND.

    Africa CDC and WHO are also establishing a joint financial tracking mechanism to monitor funding needs, commitments and gaps.

    The plan focuses on core areas: emergency coordination, surveillance, laboratory testing, infection prevention and control, clinical care, and community engagement.

    It also provides for research, logistics, and the continuity of essential health services, which are often disrupted during outbreaks.

    Experience shows that success depends on how well these elements function together.

    Surveillance must lead quickly to testing. Testing must trigger isolation and care;

    Infection prevention must protect health workers and patients;

    And community engagement must be continuous, grounded in trust, and responsive to concerns.

    This plan builds directly on national response plans in the DRC and Uganda, where authorities are intensifying efforts to bring the outbreak under control.

    It also supports preparedness in neighbouring countries, where cross-border movement creates ongoing risk.

    WHO is engaged at all three levels to support the response.

    But technical work alone is not enough. Containing Ebola depends on political commitment, sustained financing, and the trust and engagement of communities.

    This plan places communities at the centre, because without their participation, contact tracing falters, safe care is delayed, and transmission continues.

    Misinformation is almost as dangerous as the virus itself, and spreads just as fast.

    Earning and keeping the trust of communities is at the heart of everything we do.

    We are not starting from zero. This plan draws on lessons from previous Ebola outbreaks and recent health emergencies.

    Those lessons are clear: speed matters, coordination matters, and consistency matters.

    The opportunity now is to act with clarity and discipline, using a common plan to guide a common effort.

    If we do that, we can bring this outbreak to an end and strengthen the systems that protect people from the next one.

    This is a serious outbreak and it’s one we know how to stop but we need to move fast and together.

    No country faces this alone.

    As I said earlier, the key to this plan is partnership, especially between the Africa CDC and WHO.

    I’m therefore pleased to invite the Director-General of the Africa CDC, Dr Jean Kaseya, to say a few words.

    Jean, over to you.

Source: 


Link: https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-launch-of-joint-bundibugyo-ebola-virus-continental-strategic-preparedness-and-response-plan-5-june-2026

____

#Africa #CDC and #WHO launch joint #continental #Ebola #response plan (June 5 '26)

 


    The Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health Organization (WHO) today launched a joint continental preparedness and response plan on the ongoing Ebola outbreak caused by the Bundibugyo virus

    The plan aims to raise US$ 518 million to support African countries together with partners to prepare for, rapidly detect and respond to the outbreak.

    The six-month plan, covering June to November 2026, brings together governments, partners and communities under a unified ‘One Response’ approach to strengthen outbreak response measures, including emergency coordination, disease surveillance, laboratory testing, infection prevention and control, clinical care, community engagement, research, logistics and support for essential health services.

    The plan complements national response plans launched by the Governments of the Democratic Republic of the Congo and Uganda.

    “The only way to beat this outbreak is through close partnership, working together under the leadership of the affected countries in one coordinated effort, guided by a simple principle: one plan, one budget, one team,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. 

    “Containing Ebola depends on political commitment, sustained financing, and the trust and engagement of communities. This plan places communities at the centre, because without their participation, contact tracing falters, safe care is delayed, and transmission continues.”

    Dr Jean Kaseya, Director-General of Africa CDC, said: “Ebola moves fast. Africa must move faster. This joint plan gives the continent a clear path to act with speed and unity: to save lives, support the affected countries and protect neighbouring communities. With Member States, WHO and partners, Africa CDC is turning commitment into action and resources into response for the communities at risk.”

    The plan also focuses on protecting vulnerable populations, strengthening cross-border collaboration, and supporting countries to respond quickly to new cases. At a time when there are no licensed vaccines or therapeutics specifically approved for the Bundibugyo species of Ebola, the plan aims to strengthen health systems to ensure resilience even as countries respond to acute health emergencies.

    Implementation of preparedness and response activities is already underway across affected and at-risk countries. Furthermore, in 10 priority countries critical measures are being strengthened to enhance public health emergency preparedness and ensure early detection and swift response.

    The plan emphasizes the need to maintain support for other ongoing health emergencies, including mpox, cholera and measles, to prevent disruptions to critical response efforts and safeguard progress towards stronger, more resilient health systems.

    This coordinated effort comes as response operations accelerate in the Democratic Republic of the Congo, where authorities, with support from Africa CDC, WHO and partners, are ramping up efforts to curb the spread of the virus and end the outbreak.

    Africa CDC and WHO urge Member States to strengthen screening and public health measures at points of entry and enhance cross-border coordination and solidarity to support a timely, effective and evidence-based response to the outbreak.

    Through the joint preparedness and response plan, the continent is mobilising its collective expertise and resources to reinforce response measures, acting as one to control the outbreak and protect communities across the region. Its successful implementation will require strong political commitment, sustained investment and close collaboration among governments, health workers, communities and partners.

    Drawing on lessons learned from previous Ebola outbreaks and recent public health emergencies, the plan also provides a pathway to broadly strengthen Africa’s capacity to prevent, detect and respond to future health threats while protecting lives and livelihoods.

(...)

Source: 


Link: https://www.who.int/news/item/05-06-2026-africa-cdc-and-who-launch-joint-continental-ebola-response-plan

____

#Influenza at the #human - #animal #interface - #Summary and #risk #assessment, from 1 April to 8 May 2026{1} (#WHO, June 5 '26)

 


New human cases{2}: 

    ° From 1 April to 8 May 2026, based on reporting date, detections of influenza A(H5N1) in three humans, influenza A(H5N6) in one human, influenza A(H9N2) in five humans, and influenza A(H1N2) variant ((H1N2)v) virus in one human were reported officially. 


Circulation of influenza viruses with zoonotic potential in animals

    ° High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for Animal Health (WOAH).{3} 

    ° The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 

    ° Additionally, low pathogenicity avian influenza viruses as well as swine influenza viruses continue to circulate in animal populations. 


Risk assessment{5}: 

    ° Sustained human to human transmission has not been reported associated with the above-mentioned human infection events

    ° Based on information available at the time of this risk assessment update, the overall public health risk from currently known influenza A viruses detected at the human-animal interface has not changed and remains low

    ° At present, these viruses are not thought to be capable of sustained human-to-human transmission, although this could change as they evolve.  

    ° Although human infections with viruses of animal origin are infrequent, they are not unexpected at the human-animal interface.  


IHR compliance{6}: 

    ° This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin (HA) gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. 

    ° Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.  


Avian influenza viruses in humans A(H5N1), Bangladesh  

    ° On 23 April 2026, Bangladesh notified WHO of one laboratory-confirmed human case of avian influenza A(H5) infection in a child from Sylhet Division. 

    ° The patient developed fever and cough on 27 March 2026 and was admitted to hospital on 28 March with a clinical diagnosis of measles with bronchopneumonia

    ° As part of hospital-based influenza surveillance, a sample was collected on 29 March and received by the Institute of Epidemiology, Disease Control and Research (IEDCR) on 20 April. 

    ° The sample tested positive for influenza A(H5N1) on the same day by real-time reverse transcription polymerase chain reaction (RT-PCR). 

    ° The patient was discharged on 30 March

    ° No additional cases were reported among identified contacts

    ° Epidemiological investigations identified exposure to household poultry.  

    ° This is the second laboratory-confirmed human case of avian influenza A(H5N1) reported in Bangladesh in 2026. 


A(H5N1), Cambodia 

    ° On 22 April 2026, Cambodia notified WHO of one laboratory-confirmed human case of avian influenza A(H5) infection in a 66-year-old woman with comorbidities from Svay Rieng province. 

    ° The patient developed symptoms on 15 April 2026 and was admitted to district hospital on 16 April and provincial hospital the next day. 

    ° As part of severe acute respiratory infection surveillance, a sample was collected on 17 April and received by the National Institute of Public Health on 21 April. 

    ° The sample tested positive for influenza A(H5N1) on the same day by real-time RT-PCR, and the result was confirmed by Institut Pasteur du Cambodge on 22 April. 

    ° The patient died on 22 April

    ° No additional cases were reported among 15 identified contacts

    ° Epidemiological investigations identified exposure to sick and dead household chickens prior to illness onset.  

    ° Four human infections with A(H5N1) viruses have been confirmed in Cambodia in 2026, including one fatal case. 

    ° Influenza A(H5N1) viruses continue to be detected in domestic birds in Cambodia in 2026, including in areas where human cases have been detected. 

    ° Where the information is available, the genetic sequence data from the viruses from the human cases closely matches that from recent local animal viruses and are identified as clade 2.3.2.1e viruses

    ° From the information available thus far on these recent human cases, there is no indication of human-to-human transmission of the A(H5N1) viruses.   


A(H5N1), India 

    ° On 27 March 2026, India notified WHO of one laboratory-confirmed human case of avian influenza A(H5N1) infection in a child from West Bengal state. 

    ° The patient developed fever and cough and was admitted to hospital on 19 March. 

    ° The patient was discharged on 23 March

    ° Laboratory testing at the Indian Council of Medical Research (ICMR) National Institute of Virology in Pune confirmed influenza A(H5N1). 

    ° Genomic sequencing identified the virus as belonging to clade 2.3.2.1a, closely related to strains previously reported from Bangladesh and India in 2025. 

    ° No additional cases were reported among identified contacts. 

    ° Epidemiological investigations identified likely indirect exposure to poultry.  

    ° This is the first laboratory-confirmed human case of avian influenza A(H5N1) reported in India in 2026


A(H5N6), China 

    ° On 29 April 2026, China notified WHO of one laboratory-confirmed human case of avian influenza A(H5N6) infection in a 55-year-old female with comorbidities from Chongqing Municipality. 

    ° She had onset of symptoms on 16 April 2026 and was hospitalized on 23 April with severe pneumonia.  

    ° The patient died on 3 May 2026

    ° She had slaughtered and prepared poultry prior to onset of symptoms. 

    ° Environmental samples collected from the food preparation tools at the patient’s residence tested positive for influenza A(H5). 

    ° No further cases were detected among contacts of the patient. 

    ° This is the first laboratory-confirmed human case of infection with an A(H5N6) virus detected since 2024


    According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in Africa, the Americas, Asia and Europe

    Infections in non-human mammals are also reported, including in marine and land mammals.{7} 

    A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{8}   


Risk assessment for avian influenza A(H5) viruses:   

    1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5) viruses?   

        ° Most human infections so far have been reported in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. 

        ° As long as the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but remain unusual. 

        ° The impact for public health if additional sporadic cases are detected is minimal

        ° The current overall global public health risk is low

    2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H5) viruses related to the events above?   

        ° No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5) viruses. 

        ° There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. 

        ° In 2007 and the years prior, small clusters of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.   

        ° Current evidence suggests that influenza A(H5) viruses related to these events did not acquire the ability to efficiently transmit between people.  

    3. What is the likelihood of international spread of avian influenza A(H5) viruses by travellers?   

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

        ° If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.   


A(H9N2), China  

    ° Between 7 April and 6 May 2026, China notified WHO of five laboratory-confirmed cases of A(H9N2) virus infection. 

    ° The first case had comorbidities and developed severe pneumonia

    ° All the cases except the child from Jiangxi had exposure to live bird markets or household birds. 

    ° Samples from environments associated with the likely area of exposure of some of these cases tested positive for A(H9) viruses. 

    ° No further cases were detected among contacts of these cases.   


Risk assessment for avian influenza A(H9N2):  

    1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?  

        ° Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments

        ° Most human infections of A(H9N2) to date have resulted in mild clinical illness

        ° Since the virus is endemic in poultry in multiple countries in Africa and Asia, additional human cases associated with exposure to infected poultry or contaminated environments are expected but remain unusual. 

        ° The impact to public health if additional sporadic cases are detected is minimal

        ° The overall global public health risk is low.  

    2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses related to these events?  

        ° At the present time, no sustained human-to-human transmission has been identified associated with the recently reported human infections with A(H9N2) viruses. 

        ° Current evidence suggests that A(H9N2) viruses from these cases did not acquire the ability of sustained transmission among humans.  

    3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?  

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

        ° If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.  


Swine influenza viruses in humans  

Influenza A(H1N2)v, United States  

    ° On 2 May 2026, the United States notified WHO of a laboratory-confirmed case of A(H1N2)v influenza virus infection in an individual under 18 years of age from Nebraska

    ° The patient had onset of mild illness in early April 2026 and has recovered. 

    ° A respiratory specimen collected in mid-April as part of routine surveillance was sent to the US Centers for Disease Control and Prevention (CDC). 

    ° Real-time RT-PCR testing by CDC determined the sample was positive for an influenza A(H1N2)v virus

    ° Additional genetic and virologic characterization is currently underway

    ° Local public health investigations did not identify direct or indirect exposure to swine. 

    ° One household contact had mild respiratory illness also in early April but no additional cases of A(H1N2)v were identified at the time of reporting.{9} 

    ° This is the first human A(H1N2)v infection detected in the United States in 2026.  


Risk assessment for swine influenza viruses:   

    1. What is the public health risk of additional human cases of infection with swine influenza viruses?   

        ° Swine influenza viruses circulate in swine populations in many regions of the world. 

        ° Depending on geographic location, the genetic characteristics of these viruses differ. 

        ° Most human cases are exposed to swine influenza viruses through contact with infected animals or contaminated environments. 

        ° Human infection tends to result in mild clinical illness in most cases. 

        ° Since these viruses continue to be detected in swine populations, further human cases are expected. 

        ° The impact to public health if additional sporadic cases are detected is minimal

        ° The overall risk of additional sporadic human cases is low.   

    2. What is the likelihood of sustained human-to-human transmission of swine influenza viruses?    

        ° No sustained human-to-human transmission was identified associated with the event described above. 

        ° Current evidence suggests that contemporary swine influenza viruses have not acquired the ability of sustained transmission among humans.  

    3. What is the likelihood of international spread of swine influenza viruses by travellers?    

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

        ° If this were to occur, further community level spread is considered unlikely as current evidence suggests that these viruses have not acquired the ability to transmit easily among humans.  


Overall risk management recommendations

    ° Surveillance and investigations 

        Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published guidance on surveillance for human infections with avian influenza A(H5) viruses. 

        As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

        Countries should increase avian influenza surveillance in domestic and wild birds, enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, share genetic sequences of avian influenza viruses in publicly available databases, implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{10} More guidance can be found from WOAH and FAO. 

        When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: enhanced surveillance in local influenza-like illness (ILI)/SARI systems, active screening in hospitals and of groups that may be at higher occupational risk of exposure, and inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

        Vigilance for the emergence of novel influenza viruses with pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance. 

    ° Notifying WHO 

        All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{11,12} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed{13} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{14}. Evidence of illness is not required for this report. Evidence of illness is not required for this report. 

        WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions

    ° Virus sharing and risk assessment 

        It is critical that these influenza viruses from animals or from humans are fully characterized in appropriate animal or human health influenza reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{15} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

        The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. TIPRA maps relative risk amongst viruses assessed using multiple risk elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA risk assessments are published at http://www.who.int/teams/global-influenza-programme/avianinfluenza/tool-for-influenza-pandemic-risk-assessment-(tipra).  Risk reduction 

        Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

        WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 

    ° Trade and travellers 

        WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

        WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

    WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

    WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

    WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

    WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

    Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

    Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

    World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

    Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

    WOAH/FAO Network of Expertise on Animal Influenza (OFFLU) http://www.offlu.org/ 

(...)


{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810

{6} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005). Available at: https://www.who.int/publications/m/item/case-definitions-for-the-four-diseases-requiring-notification-towho-in-all-circumstances-under-the-ihr-(2005).  

{7} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{8} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en

{9} US CDC. FluView week 17, 8 May 2026 (https://www.cdc.gov/fluview/surveillance/2026-week-17.html). 

{10} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024 (https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/). 

{11} World Health Organization. International Health Regulations (2005), as amended through resolutions WHA67.13 (2014), WHA75.12 (2022), and WHA77.17 (2024) (https://apps.who.int/gb/bd/pdf_files/IHR_20142022-2024-en.pdf). 

{12} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005) (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)). 

{13} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011) (https://apps.who.int/iris/handle/10665/44518). 

{14} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition (https://iris.who.int/handle/10665/341850). 

{15} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017) (https://apps.who.int/iris/handle/10665/259402). 

Source: 


Link: https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--8-may-2026

____

My New Space

Most Popular Posts